



One Year Evaluation of Endothelial Cell Density Following iTrack™ to be Spotlighted at ESCRS 2021

Fremont, California, 1 October 2021 – Nova Eye Medical Limited, a medical technology company committed to advanced ophthalmic treatment technologies and devices, is pleased to report that the 12-month results of a five-year prospective, multi-center study by US glaucoma surgeons David Lubeck, MD, and Robert Noecker, MD, MBA, to assess endothelial cell density following iTrack™ performed in conjunction with cataract surgery will be presented at the 39th Congress of the European Society of Cataract and Refractive Surgery (ESCRS), October 8-11, 2021.

In the prospective study, seventy-seven (77) eyes of 46 open-angle glaucoma (OAG) patients, classified as either mild, moderate or severe disease, were treated with canaloplasty in combination with cataract surgery.

The 12-month data reported a mean change in endothelial cell density (ECD) of -3.2% (SD ± 9.0%).

It is well known that traditional glaucoma surgeries, such as trabeculectomy and tube shunts, are associated with progressive ECL, which may lead to corneal decompensation and subsequent vision loss. According to Dr. Lubeck, some MIGS procedures may also introduce a greater risk of endothelial cell loss based on the redirection of aqueous currents. Specifically, the creation of artificial flow which directs the aqueous humor to one or two points of exit.

“iTrack™ improves outflow facility without redirecting aqueous currents, and without the use of an implant or the removal of tissue. Our data to be presented at the ESCRS 2021 suggests that this approach may safeguard against the risk of excessive damage to the corneal endothelium,” commented Dr. Lubeck.

In addition to evaluating the impact of iTrack™ on corneal health, doctors Lubeck and Noecker also evaluated the clinical outcomes of iTrack™ in reducing mean intraocular pressure (IOP) and medication burden at 12 months.



Dr Lubeck's ESCRS iTrack™ abstract (PP137) can be accessed via the following link:
<https://congress.es CRS.org/wp-content/uploads/2021/09/ESCRS-2021-Poster-Cataract.pdf>
(Refer to page 127)

All educational content of the ESCRS annual meeting is planned by its program committee, and ESCRS does not endorse, promote, approve or recommend the use of any products, devices or services.

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include iTrack™ minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe or complex glaucoma. It also offers the benefit of a simplified and faster surgical profile. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by sales offices in Adelaide, Australia and Berlin, Germany, and a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit:
www.nova-eye.com

For additional information about canaloplasty, please visit: www.canaloplasty.com

Indication For Use: The iTrack Canaloplasty Microcatheter is indicated for fluid infusion and aspiration during surgery. The iTrack Canaloplasty Microcatheter is indicated for catheterization and viscodilation of Schlemm's canal to reduce intraocular pressure in adult patients with open angle glaucoma. (For full safety information visit <https://glaucoma-itrack.com/safety>.)